Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$13.75
$13.74
$4.41
$13.80
$477.47M0.89950,664 shsN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$2.00
+0.3%
$1.64
$1.17
$21.92
$12.08M0.041.22 million shs300,875 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.68
-2.2%
$1.67
$1.15
$3.47
$11.46M-0.3422,278 shs3,237 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.52
-2.2%
$3.37
$2.23
$4.13
$178.67M1.29413,289 shs186,737 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.01
+233.3%
$0.03
$0.00
$6.93
$241K1.318.06 million shs54,905 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%+2.04%+0.50%+10.50%-88.64%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-2.17%-1.47%-6.94%+15.52%-49.70%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-2.22%-0.85%-2.22%+24.82%+15.79%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
+233.33%-64.14%-64.14%-62.50%-99.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
4.1307 of 5 stars
3.34.00.04.50.61.70.6
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.1381 of 5 stars
3.04.00.04.61.90.01.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.2943 of 5 stars
3.52.00.00.02.54.23.1
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.3675 of 5 stars
3.15.00.04.31.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00
N/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.67
Moderate Buy$42.602,030.00% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00198.51% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.0098.86% Upside
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3336,937.04% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$327.75M1.46N/AN/A$7.37 per share1.87
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$2.27M5.34N/AN/A($30.01) per share-0.07
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.20 per share8.19($3.67) per shareN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.76$0.83 per share4.23$1.88 per share1.87
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.63N/AN/A$0.79 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.04N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.579.26N/A16.37%49.35%18.25%7/30/2025 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)

Latest SYRS, NERV, PBYI, BTAI, and AMAG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.11N/AN/AN/AN/AN/A
8/5/2025Q2 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.30N/AN/AN/A$0.21 millionN/A
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
5/12/2025Q1 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
1.13
1.75
1.45
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
1.48
1.45
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
CompanyEmployeesShares OutstandingFree FloatOptionable
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
44034.73 millionN/AOptionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
906.06 million4.77 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 millionN/ANot Optionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable

Recent News About These Companies

Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
SYRS’s Latest Surge: What’s Behind the Spike?

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMAG Pharmaceuticals stock logo

AMAG Pharmaceuticals NASDAQ:AMAG

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$2.00 +0.01 (+0.25%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.00 0.00 (-0.25%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.68 -0.04 (-2.17%)
Closing price 07/10/2025 03:57 PM Eastern
Extended Trading
$1.63 -0.05 (-2.69%)
As of 07/10/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.52 -0.08 (-2.22%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$3.54 +0.02 (+0.57%)
As of 05:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0090 +0.01 (+233.33%)
As of 07/10/2025 03:58 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.